Design and Analysis of Bioavailability and Bioequivalence Studies, Second Edition
Marcel Dekker Inc (Publisher)
2nd Edition
Published on 24. November 1999
Book
Hardback
600 pages
978-0-8247-7572-8 (ISBN)
Article exhausted; check for reprint
Description
"Provides a comprehensive summary of the continuously growing literature and research activities on the regulatory requirements, scientific and practical issues, and statistical methodology of the design and analysis of bioavailability and bioequivalence studies. Includes several new chapters."
More details
Series
Edition
2nd New edition
Language
English
Place of publication
New York
United States
Publishing group
Taylor & Francis Inc
Target group
College/higher education
Professional and scholarly
Edition type
New edition
Dimensions
Height: 229 mm
Width: 152 mm
Weight
839 gr
ISBN-13
978-0-8247-7572-8 (9780824775728)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions

Shein-Chung Chow | Jen-pei Liu
Design and Analysis of Bioavailability and Bioequivalence Studies
Book
10/2008
3rd Edition
Chapman & Hall/CRC
€202.50
Shipment within 15-20 days
Previous edition
Shein-Chung Chow | Jen-pei Liu
Design and Analysis of Bioavailability and Bioequivalence
Book
01/1992
Marcel Dekker Inc
€122.56
Shipment within 15-20 days
Persons
Author
Duke University School of Medicine
National Taiwan University, Taipei
Content
Designs of bioavailability studies; statistical inferences for effects from a standard 2x2 crossover design; statistical methods for average bioavailability; power and sample size determination; transformation and analysis of individual subject ratios; the assessment of inter- and intrasubject variabilities; assumptions and outliers detection; optimal crossover designs for two formulations; assessment of bioequivalence for more than two formulations; assessment of bioequivalence for drugs with negligible plasma levels; some related problems in bioavailability studies; metanalysis for bioequivalence - review; population and individual bioequivalence; review of FDA guidances. Appendices: statistical tables; SAS programs.